(NYSE: RCUS) Arcus Biosciences's forecast annual revenue growth rate of 7.98% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.27%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.52%.
Arcus Biosciences's revenue in 2026 is $117,000,000.On average, 14 Wall Street analysts forecast RCUS's revenue for 2026 to be $11,047,698,369, with the lowest RCUS revenue forecast at $6,663,610,233, and the highest RCUS revenue forecast at $20,322,406,810. On average, 14 Wall Street analysts forecast RCUS's revenue for 2027 to be $15,302,925,128, with the lowest RCUS revenue forecast at $0, and the highest RCUS revenue forecast at $47,389,662,546.
In 2028, RCUS is forecast to generate $18,585,579,561 in revenue, with the lowest revenue forecast at $8,485,496,177 and the highest revenue forecast at $33,947,078,042.